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Abstract
Retinoic acid (RA), an active metabolite of Vitamin A, and bone morphogenetic protein 4 
(BMP-4) pathways control the transcription of pro-opiomelanocortin (Pomc), the precursor 
of ACTH. We describe a novel mechanism by which RA and BMP-4 act together in the 
context of pituitary corticotroph tumoral cells to regulate Pomc transcription. BMP-4 
and RA exert a potentiated inhibition on Pomc gene expression. This potentiation of 
the inhibitory action on Pomc transcription was blocked by the inhibitory SMADs of the 
BMP-4 pathway (SMAD6 and SMAD7), a negative regulator of BMP-4 signaling (TOB1) and 
a blocker of RA pathway (COUP-TFI). AtT-20 corticotrophinoma cells express RA receptors 
(RARB, RXRA and RXRG) which associate with factors of BMP-4 (SMAD4 and SMAD1) 
signaling cascade in transcriptional complexes that block Pomc transcription. COUP-TFI 
and TOB1 disrupt these complexes. Deletions and mutations of the Pomc promoter and 
a specific DNA-binding assay show that the complexes bind to the RARE site in the Pomc 
promoter. The enhanced inhibitory interaction between RA and BMP-4 pathways occurs 
also in another relevant corticotroph gene promoter, the corticotropin-releasing hormone 
receptor 1 (Crh-r1). The understanding of the molecules that participate in the control of 
corticotroph gene expression contribute to define more precise targets for the treatment 
of corticotrophinomas.
Introduction
Retinoic acid (RA), the active acid metabolite of Vitamin 
A, is a regulator of metabolic and cellular functions like 
cell differentiation, proliferation and apoptosis. RA acts 
mainly through a canonical pathway of gene expression 
regulation that involves the binding to nuclear RA 
receptors, which interact with specific regions in the 
DNA (Das et  al. 2014) and are divided in two classes: 
RA receptors (RAR) and retinoid X receptors (RXRs). 
Three isoforms were described for RAR receptors, RARA, 
RARB and RARG, while RXRA, RXRB and RXRG were 
described for RXR receptors (Maden 2007). Due to 
the ample variety of systemic processes in which RA 
participates, RA-modulating drugs have been used in 
certain clinical settings showing beneficial biological 
effects (Burnett et al. 2015, Abaza et al. 2017).
Cushing’s disease originates in the excessive 
production of adrenocorticotropic hormone (ACTH) by 
a secreting pituitary corticotrophinoma and as a result 
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of this over-production, the systemic level of circulating 
cortisol produced by the adrenal glands is dramatically 
increased (Dahia & Grossman 1999, Melmed 2015, Albani 
et al. 2018). Corticotroph adenomas derive from normal 
pituitary corticotroph cells and represent about 4–8% 
of the hormone-active tumors in the anterior pituitary 
(Dahia & Grossman 1999). Cushing’s disease is a very 
low-incidence disorder with the prevalence of active 
corticotroph tumors being about 40 cases per million, 
with higher prevalence in women (Pivonello et al. 2015). 
Transsphenoidal surgery is, in principle, the first approach 
for a treatment. This surgery procedure is not always 
successful, especially when the tumor is not completely 
resected, in which case, over time might expand, 
generating the necessity of other therapeutical options 
like chemotherapy, radiotherapy, repeated surgery or 
pharmacological treatment. In some cases, adrenalectomy 
is the decision of choice (Pivonello et al. 2015). Therapies 
aiming to reduce the circulating cortisol mainly act directly 
on the adrenal cortex by either blocking the synthesis of, 
or antagonizing peripheral glucocorticoid receptors, thus 
inhibiting glucocorticoid action or modulating ACTH 
pituitary hormone secretion (Pedroncelli 2010, Fleseriu 
& Castinetti 2016, Fuertes et  al. 2018, Grossman 2018, 
Langlois et al. 2018). Despite the ample variety of current 
available therapies (Fuertes et al. 2018), none has proven 
to be effective and to reliably provide a good, recurrence-
free quality of life to the patient (Mooney et  al. 2016, 
Bertagna 2018). The genetic and cellular mechanisms 
that underlie corticotrophinomas are poorly understood 
(Newell-Price et al. 2006), partially explaining the lack of 
effective treatments (Pivonello et al. 2015).
ACTH is derived from a 266 amino acid precursor 
polypeptide, pro-opiomelanocortin (Pomc) (Drouin 
2016). The Pomc gene plays a central role among 
the hypothalamic–pituitary–adrenal axis regulatory 
mechanisms (Gagner & Drouin 1985, Ray et al. 1995). The 
transcription activity of this gene is highly upregulated 
in ACTH-secreting pituitary adenomas (Arzt et  al. 
1992, Dahia & Grossman 1999), thus suggesting Pomc 
transcriptional regulatory mechanisms as potential 
pharmacological targets. Recently, it was shown that 
proton-induced corticotropin-releasing hormone receptor 
1 (Crh-r1) signaling regulates Pomc expression and ACTH 
production (Kameda et al. 2019).
Given its known role of inhibiting Pomc transcription, 
RA signaling is attractive as a target for long-term 
treatments. In this regard, RA treatment reduced ACTH 
secretion in the murine AtT-20 corticoptrophinoma-
like cell line and the proliferation rate of these cells 
(Paez-Pereda et  al. 2001). In vivo tumorigenesis studies 
using nude mice showed that RA treatment blocked the 
growth of corticotroph tumors compared to vehicle-
treated ones, reverting the characteristic signs of high 
corticosterone levels (Paez-Pereda et al. 2001). A 6-to-12-
month treatment scheme with RA in dogs with Cushing’s 
disease not only normalized cortisol levels but prevented 
pituitary adenomas from recurring as well (Castillo et al. 
2006). Two prospective clinical trials in human patients 
reported beneficial results in normalizing ACTH and 
cortisol levels after treatment with RA, for a period of 6–12 
months (Pecori Giraldi et al. 2012, Vilar et al. 2016). The 
orphan nuclear receptor COUP-TFI negatively regulates 
retinoid action on target genes (Schuh & Kimelman 1995, 
Bertacchi et  al. 2019). Consistent with the presence of 
COUP-TFI in normal pituitary cells and not in tumoral 
ones, ACTH levels were unaltered after RA treatment in 
non-tumoral corticotrophs (Paez-Pereda et al. 2001).
Interestingly, RA treatment induces the expression of 
bone morphogenetic protein-4 (BMP-4), a cytokine of the 
TGFB superfamily involved in multiple tissue and organ 
maturation and differentiation processes, particularly 
during pituitary development (Sheng et al. 1997, Cushman 
& Camper 2001, Davis et  al. 2011). The mechanism 
mediating these actions involves the activation of 
specific signal transducers, the Smad proteins, which 
migrate to the nucleus to act as transcription factors (Shi 
& Massague 2003). Drugs acting at the epigenetic level 
have a permissive action for RA-induced expression of the 
BMP gene in pituitary tumor cells (Yacqub-Usman et  al. 
2013). The expression of BMP-4 is reduced in Cushing’s 
corticotrophinoma cells compared to corticotrophs from 
normal pituitary glands (Giacomini et al. 2006). Reduced 
expression of BMP-4 in corticotrophinomas is associated 
with epigenomic silencing, and the coincubation with the 
demethylating agent zebularine or the histone deacetylase 
inhibitor, trichostatin A, reversed the epigenetic changes 
and restored the expression of BMP-4 (Yacqub-Usman 
et  al. 2012). BMP-4 treatment reduced ACTH secretion 
and proliferation of AtT-20 mouse corticotrophs, effects 
which were blocked in stably expressing SMAD4-DN or 
noggin AtT-20 clones (Giacomini et  al. 2006). BMP-4 
represses Pomc promoter activity involving SMAD1/4 
and the interference with Pitx/Tpit activity (Nudi et  al. 
2005). Tob1, a transcription factor participating in 
bone formation processes by blocking BMP-4/SMAD1/7 
signaling in osteoblasts (Yoshida et al. 2000), takes part in 
the molecular events that control the actions of BMP-4 .
To understand the regulatory mechanisms of Pomc 
expression by RA we analyzed in depth the signaling 
AUTHOR COPY ONLY
https://doi.org/10.1530/JME-19-0059
https://jme.bioscientifica.com © 2019 Society for Endocrinology
Printed in Great Britain
Published by Bioscientifica Ltd.
16363 3:L Nieto, M Fuertes et al. BMP-4 and RA pathways on 
corticotrophs
Journal of Molecular 
Endocrinology
receptors involved in the interaction with BMP-4 signaling 
pathways and their joint action on the inhibition of 
Pomc transcription. The observed interaction of both 
pathways, at transcriptional level, resulted in a marked 
inhibition of the mechanism leading to production of 
ACTH, evidencing an interconnected regulatory network. 
Complexes between the RA receptors and SMAD signaling 
molecules that are negatively regulated by COUP-TFI and 
Tob1 contribute to the transcriptional control of Pomc 
and provide the molecular basis to understand the action 
of both BMP-4 and RA on the Pomc–-ACTH expression 
in corticotrophs.
Materials and methods
Unless otherwise stated, reagents were obtained from 
Life Technologies/Thermo Fisher Scientific or Sigma-
Aldrich/Merck.
Cell culture
AtT-20 pituitary corticotroph tumor cells were obtained 
from the American Type Culture Collection. AtT-20 
cells were cultured in low-glucose DMEM (pH 7.3) 
supplemented with 10% fetal calf serum (FCS), 2.2 g/L 
NaHCO3, 10 mM HEPES, and 2 mM glutamine until they 
were confluent under 5% CO2 atmosphere at 37°C. Cells 
were treated with 100 ng/mL BMP-4 (R&D Systems) or 
100 nM all-trans RA that was dissolved in ethanol-DMSO 
as a 10 mM stock solution and handled in the dark. The 
diluting mixture was used in all the in vitro experiments 
as control.
Plasmids
The luciferase gene under the control of 770 bp of the rat 
Pomc promoter includes all the necessary sequences for 
the expression and regulation of Pomc in pituitary cells 
in vivo (Liu et  al. 1992). The following Pomc promoter 
reporter constructs that present deletions or mutations 
in the Pomc promoter useful for our studies (Fig. 3A) 
were kindly given by Jacques Drouin (Therrien & Drouin 
1991): JA289 (which contains a BMPRE deletion), JA361 
(which contains a RARE deletion), JA316 (which contains 
a BMPRE point mutation) and JA327 (which contains a 
RARE point mutation). RARE-LUC reporter was kindly 
provided by Ethan Dmitrovsky (Petty et al. 2005). 
BMPRE-LUC and mouse TOB1 expression vector were 
generously given by Yutaka Yoshida (Yoshida et  al. 
2000). SMAD6 and SMAD7 expression vectors were 
kindly given by Takeshi Imamura and Peter ten Dijke, 
respectively (Imamura et  al. 1997, Nakao et  al. 1997). 
COUP-TFI expression vector was kindly given by Ming-Jer 
Tsai (Pipaon et  al. 1999). Crh-r1–-LUC reporter vector is 
described elsewhere and was kindly given by Alon Chen 
(Kuperman et al. 2011).
Transfection and reporter assays
Cell transfection was performed with Lipofectamine and 
Plus Reagent according to manufacturer instructions and 
using standard procedures, as previously described (Paez-
Pereda et al. 2001, Giacomini et al. 2006). After plating in 
12-well plates, cells were transfected for 6 h in OPTIMEM 
using 2 µL of Lipofectamine, 1 µL of Plus Reagent and 
1 µg total plasmid DNA per well. Cells were then washed 
and left to recover in DMEM overnight. The following 
day, cells were washed, left in serum-free DMEM for 
6 h and treated for 24 h in serum-free DMEM with the 
indicated compounds. An additional 200 ng of the RSV-
β-gal construct was co-transfected in all the experiments 
to correct for variations in transfection efficiency as 
previously described (Paez-Pereda et al. 2003). Luciferase 
activity was measured with a Junior luminometer 
(Berthold, Bad Wildbad, Germany). Results are shown as 
ratios of luciferase and/β-galactosidase activity.
For transfections with SMAD6 and 7 expression 
vectors a dose–response curve was assayed from 0 to 
500 ng of each plasmid and a dose of 100 ng was chosen 
for subsequent studies as this dose showed no alteration 
in basal activation levels.
A dose–response curve of TOB1 on Pomc transcription 
showed that from 100 to 300 ng, it stimulates the basal 
condition and most effectively blocks BMP-4 at 300 ng.
Western blot analysis
Western blot (WB) was performed as previously described 
(Paez-Pereda et al. 2003). Briefly AtT-20 cells were washed 
once with PBS (pH 7.0), and then cell lysates were 
prepared in standard cracking buffer and boiled for 5 min. 
Equal levels of protein (30 µg) were electrophoresed by 
SDS-PAGE. Proteins were blotted onto nitrocellulose 
Western blotting membranes (Amersham) using standard 
procedures and anti-RXRA (sc-553, 1:1,000), anti-RXRB 
(sc-56869, 1:1,000), anti-RXRG (sc-555, 1:1,000), anti-
RARA (sc-551, 1:1,000), anti-RARB (sc-552, 1:1,000), 
anti-RARG (sc-7387, 1:1,000), anti-SMAD4 (sc-7966, 
1:1,000), anti-SMAD1 (sc-7965, 1:1000) or anti-Actin 
(sc-47778, 1:5,000) (Santa Cruz Biotechnology Inc.) or 
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anti-pSMAD1/5 (Ser463/465, 41D10) (Cell Signaling) 
were added. The primary antibodies were detected with 
HRP-conjugated anti-rabbit IgG secondary antibodies 
(Bio-Rad). Blots were imaged using the G:Box Chemi 
XT4 (Synoptics Ltd., Cambridge, United Kingdom) with 
SuperSignal West Dura kit according to manufacturer’s 
instruction (Pierce Biotechnology).
Immunoprecipitation (IP)
Cells were seeded in P100 plates to full confluence in 
DMEM. Before performing the treatment, DMEM was 
changed to serum-free DMEM for 6 h. Cells were treated in 
serum-free DMEM for 24 h with the indicated compound, 
washed with PBS, lysed on ice with modified RIPA buffer 
and immunoprecipitated with anti-SMAD4 or anti-SMAD1 
using Protein G Agarose as described (Paez-Pereda et  al. 
2003). WB analyses were performed with the indicated 
antibodies. Mock control corresponds to the condition 
with all treatments present and immunoprecipitated with 
unspecific IgG of the same isotype of the antibody used 
to precipitate.
Hormone measurements
ACTH was determined by radioimmunoassay as previously 
described (Arzt et al. 1992).
Preparation of nuclear extracts
AtT-20 cells (9 × 106) were treated with RA, BMP-4 or vehicle 
for 24 h, and then harvested in 1 mL cold PBS containing 
0.6 mM EDTA and pelleted at 5000 g for 30 s. Nuclear 
extracts were prepared as previously described (Giacomini 
et  al. 2009). Cell pellets were gently resuspended in 
350 μL cold buffer A (10 mM HEPES (pH 7.9), 10 mM 
KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol 
(DTT), 0.5 mM phenylmethylsulfonyl fluoride, 1 µg/mL 
aprotinin and 1 μg/mL pepstatin) and allowed to swell on 
ice for 10 min; then 5 mL of a 10% Igepal CA-630 solution 
was added to the cell suspensions, and cells were lysed 
on ice for 10 min and vortexed for 5 s every 2 min. After 
centrifugation at 12,000 g for 20 min, the nuclear pellets 
were resuspended in 100 µL cold buffer B (20 mM HEPES 
(pH 7.9), 600 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM 
DTT, 1 mM phenylmethylsulfonyl fluoride and 25% 
glycerol), incubated for 40 min on ice and vortexed every 
10 min. After removal of nuclear debris by centrifugation 
at 16,000 g for 10 min at 4°C, the microextracts were 
stored at −80°C.
EMSA
EMSA was performed as previously described (Giacomini 
et al. 2009). Oligonucleotides were synthesized as single 
strand and the annealing of the complementary strands 
was allowed. Briefly, each oligonucleotide was dissolved 
to a final concentration of 1 mg/mL before use, the 
annealing reaction was performed in oligo annealing 
buffer (100 mM Tris–HCl (pH 7.5), 1 M NaCl and 10 mM 
EDTA) and equal volumes of both oligonucleotides 
were mixed and heated in a standard heat block at 
95°C. The following oligonucleotides were annealed: 
5′-AGCGCTGCCAGGAAGGTCACGTCCAAGGCT-1 ′ 
and 5′-AGCCTTGGACGTGACCTTCC TGGCAGCG-1′. 
Oligonucleotides (1 μg) were labeled using [α-32P]-dCTP 
and large-fragment DNA polymerase I (Klenow fragment). 
For binding reactions, nuclear extracts were incubated for 
30 min at room temperature in a total volume of 30 µL 
containing 25 mM HEPES (pH 7.2), 150 mM KCl, 10 mM 
DTT, 10% glycerol, 40 mM Spermidine and 500 µg/mL 
poly(deoxyinosinic-deoxycytidylic) used as nonspecific 
competitor DNA, with 50000 cpm labeled probe. The 
samples were resolved on 6% polyacrylamide gels 
(acrylamide/bisacrylamide ratio of 29:1), buffered and ran 
for about 1.5 h in 0.5% TBE at room temperature (1× TBE 
is 45 mM Tris/borate/1 mM EDTA). Anti-Smad4 antibody, 
anti-RARβ antibody, anti-RXRα antibody or anti-actin 
antibody (Santa Cruz Biotechnology Inc.) as control, were 
added to the nuclear extracts and incubated for 30 min 
at room temperature after addition of the probe. After 
incubation, the binding reaction mixture was applied to 
the gel as described above.
Statistical analysis
Statistical analyses were performed by ANOVA in 
combination with the Bonferroni post hoc test. Data are 
shown as mean ± s.e.m.
Results
BMP-4 potentiates RA inhibitory effect on 
Pomc transcription
We first evaluated the interaction of RA and BMP-4 on 
ACTH secretion in AtT-20 cells and observed a potentiated 
inhibitory effect of RA in co-treatment with BMP-4 
(Fig. 1A). We evaluated if this interaction occurs on the 
Pomc promoter and observed that single RA or BMP-4 
treatments reduced luciferase expression in the Pomc 
reporter assay by approximately 50%, with co-treatment 
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leading to a slight but significant further reduction (Fig. 
1B). The extend of potentiation of the inhibition when 
BMP-4 was combined with RA was 16–37% with respect 
to RA alone. The inhibitory effect of RA or BMP-4 and also 
the potentiation of this inhibition by the co-treatment 
was abolished in the presence of 100 ng of the inhibitors 
of BMP-4 signaling, SMAD 6 or SMAD 7 (Fig. 1B). BMP-4 
(3.9-folds) or RA (1.9-folds) treatment increased the 
phosphorylation of SMAD1/5 (which nicely mirrors its 
action show in Fig. 1B) which was not further altered by 
the co-treatment (four-folds) (Fig. 1C). Based on this, it 
looks possible that additional phosphorylation occurs 
with co-treatment.
To further study the crosstalk of BMP-4 and RA 
signaling pathways, we evaluated the effect of the 
co-treatment with specific reporters for both cascades. 
We observed an increase in transcriptional activation of 
RARE reporter after RA treatment, thus highlighting the 
importance of the DNA context of the RARE site (Buchler 
et al. 2003, Segal & Widom 2009), which was potentiated 
by the co-treatment with BMP-4 (Fig. 1D). BMP-4 alone 
did not activate RARE transcription (Fig. 1D). In presence 
of SMAD 6 or SMAD 7, RA activated RARE transcription, 
but no activation enhancement was observed by the 
co-treatment with BMP-4 (Fig. 1D). BMP-4-specific 
SMAD-binding element reporter (BMPRE) showed 
activation by BMP-4, but no potentiated activation 
effect by the co-treatment with RA. RA alone did not 
activate BMPRE transcription (Fig. 1E). Consistent with 
cooperation between BMP and RA signaling in Pomc 
transcriptional inhibition, RA treatment failed to repress 
the Pomc reporter in AtT-20 cell clones that stably 
expressed a dominant negative SMAD4 protein (AtT-20 
SMAD4-DN) (Fig. 1F).
RA and BMP-4 signaling factors associate to form 
transcriptional complexes
AtT-20 cells express the isoforms β and γ of the RA receptors 
(RAR) family, and the isoforms α, β and γ of the RXR family 
(Fig. 2A). We studied by IP assays in cells treated with 
RA or BMP-4, whether any of these receptors associate 
with factors of the BMP-4 signaling pathway. Smad4, the 
common TGFB/BMP-SMAD signaling mediator, forms 
complexes with RARB, RXRA and RXRG (Fig. 2B). We 
studied the formation of complexes of RA receptors with 
SMAD1, a specific BMP-4 pathway signaling molecule, 
and observed interaction with RARB, RXRA and RXRG 
(Fig. 2C), the same isoforms as for SMAD4.
Pomc promoter contains putative response 
elements for RA and BMP
We analyzed the sequence of the promoter region of rat 
Pomc (−483 to +63 bp) with BLAST tool and INSECT 2.0 
software (Rohr et al. 2013, Parra et al. 2016) and found two 
putative response elements, one for RA (RARE site), located 
between the −68 and −63 bp in the proximal segment of 
the Pomc promoter, and a BMP response element (BMPRE), 
located between −423 and −419 bp in the distal segment 
of the promoter (Fig. 3A). The relevance of those sites was 
validated functionally by the loss of response to RA and 
BMP respectively (Fig. 3B and C). With different reporter 
constructs containing deletions (Fig. 3B) or mutations 
(Fig. 3C) of the Pomc promoter, we observed that in the 
reporter containing only the RARE site (Fig. 3B, Pomc 
promoter with RARE site – BMPRE deletion) both the 
inhibition by RA and the potentiation of the co-treatment 
with BMP-4 are preserved. Similar results were obtained 
in the point mutation construct for BMPRE (Fig. 3C, 
Mutated BMPRE site). In the Pomc construct containing 
only the BMPRE site (Fig. 3B, Pomc promoter with BMPRE 
site – RARE deletion), we observed no inhibitory effect by 
RA treatment and no potentiation in co-treatment with 
BMP-4. This observation was corroborated in the point 
mutation construct for RARE (Fig. 3C, mutated RARE site).
In an EMSA assay using the RARE sequence as 
radiolabeled probe to assess the formation of protein 
complexes with this sequence, we observed the formation 
of complexes for AtT-20 cell nuclear extracts after BMP-4 
or RA treatment or co-treatment. In the absence of RA, 
a binding is observed, which is in agreement with the 
constitutive complex observed with similar conditions in 
Fig. 2. The complex formed in the co-treatment condition 
was disrupted in the presence of anti-SMAD4 but not anti-
Actin, showing that SMAD4 is part of the complex that 
binds to the RARE site. Moreover, when we evaluated RA 
treatment and RA/BMP-4 co-treated condition with anti-
RARB and anti-RXRA, the complexes formed were also 
displaced by the antibodies, revealing the presence of 
these RA receptors (Fig. 3D).
COUP-TFI blocks RA-mediated transcriptional 
repression of Pomc
COUP-TFI, a known negative regulator of RA signaling, 
disrupted the formation of the transcriptional complexes 
between RXRA, RXRG or RARB with SMAD4 in all the 
treatment conditions assayed (Fig. 4A). The interaction of 
RXRA or RARB with SMAD1 (Fig. 4B) was also disrupted, 
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Figure 1
 RA inhibitory action on ACTH secretion and Pomc transcription is increased by the BMP-4 signaling pathway. (A) AtT-20 cells were treated for 24 h with 
BMP-4, RA, or their combinations as indicated, under CRH (100 nM) treatment. ACTH was measured in the supernatants by radioimmunoassay, and the 
average of three wells per treatment and s.e.m. from one representative experiment of three with similar results are shown. **P < 0.01; ***P < 0.001; 
ANOVA with Bonferroni contrast. (B) AtT-20 cells were co-transfected with Pomc-LUC reporter vector (500 ng), RSV-β-gal construct (200 ng) and SMAD6 
or SMAD7 expression vector (100 ng) or empty vector and treated with BMP-4, RA or their combination as indicated. After 24-h treatment, luciferase 
activity was measured and normalized. Values indicating the mean ± s.e.m. of luciferase to β-galactosidase ratio of one representative experiment of four 
with similar results are shown. *P < 0.05; ***P < 0.001; ANOVA with Bonferroni contrast. (C) pSMAD1/5 expression was studied by WB in AtT-20 cells 
treated with BMP-4, RA or their combination as indicated. (D) AtT-20 cells were co-transfected with RARE-LUC reporter vector (500 ng), RSV-β-gal 
construct (200 ng) and SMAD6 or SMAD7 expression vector (100 ng) or empty vector and treated with BMP-4, RA or their combination as indicated. After 
24-h treatment, luciferase activity was measured and normalized. Values indicating the mean ± s.e.m. of luciferase-to-β-galactosidase ratio of one 
representative experiment of four with similar results are shown. ***P < 0.001; n.s, not significant; ANOVA with Bonferroni contrast. (E) AtT-20 cells 
were co-transfected with BMPRE-LUC reporter vector (500 ng) and RSV-β-gal construct (200 ng), and treated with BMP-4, RA or their combination as 
indicated. After 24-h treatment, luciferase activity was measured and normalized. Values indicating the mean ± s.e.m. of luciferase-to-β-galactosidase 
ratio of one representative experiment of three with similar results are shown. **P < 0.01; n.s, not significant; ANOVA with Bonferroni contrast. (F) 
AtT-20 cells or AtT-20 SMAD4-DN stable clones were co-transfected with Pomc-LUC reporter vector (500 ng) and RSV-β-gal construct (200 ng) and treated 
with BMP-4, RA or their combination as indicated. After 24-h treatment, luciferase activity was measured and normalized. Values indicating the 
mean ± s.e.m. of luciferase-to-β-galactosidase ratio of one representative experiment of three with similar results are shown. **P < 0.01; ***P < 0.001; 
ANOVA with Bonferroni contrast.
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while that for RXRG and SMAD1 was diminished only in 
the presence of BMP-4 and RA. The expression of COUP-
TFI blocked the effect of RA treatment in both the Pomc 
and RARE reporters, as well as the potentiation exerted by 
the co-treatment with BMP-4 and RA (Fig. 4C and D). As 
a control, we further analyzed the effect of COUP-TFI in 
the Pomc promoter constructs with deletion (Fig. 4E) or 
mutation (Fig. 4F) of the BMPRE site. Consistent with the 
previous results, as expected, the presence of COUP-TFI 
blocked the inhibition exerted by the treatment with RA 
and the potentiation with BMP-4 in both Pomc constructs.
TOB1 specifically blocks BMP-4 inhibition on 
POMC transcription
We next examined whether TOB1, a negative regulator of 
the BMP-4 pathway (Yoshida et al. 2000, Cao & Chen 2005) 
affected the formation of the transcriptional complexes 
in AtT-20 cells. The expression of TOB1 hampered the 
formation of the complexes between RXRA, RXRG or RARB 
with SMAD4 (Fig. 5A). The same IP profile was obtained 
for the interaction between RXRA, RXRG or RARB with 
SMAD1 (Fig. 5B). TOB1 blocked the formation of these 
complexes though its effect was slightly less potent in 
comparison with SMAD4. The expression of TOB1 (300 ng) 
nullified the inhibitory action of BMP-4 treatment on Pomc 
and stimulated the basal condition, probably because it 
abolishes the action of the endogenous proteins (Fig. 5C). 
The potentiated activation in transcription exerted by RA 
and BMP-4 co-treatment on RARE reporter was blocked by 
the presence of TOB1, which did not block the activation 
produced by RA treatment (Fig. 5D).
RA and BMP-4 signaling interaction is also 
exhibited for Crh-r1 promoter
We next analyzed the Crh-r1 promoter in order to 
examine if the mechanism of transcriptional regulation 
shown on the Pomc promoter by the crosstalk of RA and 
BMP-4 signaling pathways, takes place also in another 
corticotroph physiologically related regulation system. 
In accordance with the analysis of the Pomc promoter, 
in the sequence of the promoter region of mouse Crh-
r1 (−2685 to +217 bp), we found with the INSECT 2.0 
software (Rohr et al. 2013, Parra et al. 2016) one putative 
response element for RA (RARE site), in addition to four 
putative response elements for BMP (BMPRE site) (Fig. 
6A). For this reporter, the transcriptional activation was 
also inhibited by the treatment of RA or BMP-4 (Fig. 
6B). RA and BMP-4 co-treatment showed a potentiated 
inhibitory response. To assess the hypothesis of BMP-4 
signaling pathway participation, the same functional 
experiment was performed in AtT-20 SMAD4-DN 
cells. In these cells, the effect of the treatment with 
RA or BMP-4 on Crh-r1 promoter was completely 
nullified (Fig. 6B).
Figure 2
AtT-20 corticotroph cells express RA receptors, 
which interact with elements of the BMP-4 
signaling pathway. (A) Retinoid and Rexinoid 
receptors (RAR and RXR) expression was studied 
by WB in AtT-20 cells and the specific band is 
indicated by an arrow. Cell extracts from HeLa (for 
RARA, RARG and RXRs) or HEK293T (for RARB) 
were used as positive controls. (B and C) AtT-20 
cells were treated for 24 h with BMP-4, RA or their 
combination as indicated. Cell lysates were IP with 
anti-SMAD4 (1 µg) (B) or anti-SMAD1 (1 µg) (C) and 
analyzed by WB. M, mock. One representative of 
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Discussion
RA and BMP-4 have shown to be involved in the 
regulation of corticotrophinoma growth and hormone 
production, but their interrelation on Pomc transcription 
had not been analyzed until now. Our work describes 
a novel mechanism by which RA receptors of both the 
RAR and RXR families interact with SMADs, the signal 
Figure 3
RARE and BMPRE sites at the Pomc promoter. (A) Schematic representation of rat Pomc promoter (GenBank: X03171.1) in which we found by in silico 
analysis two consensus sequence, one for RA (RARE site, −63 to −68) and one for BMP (BMPRE site, −419 to −423). The scheme shows the distal (dotted), 
central (gray), proximal (lined) and minimal (white) promoter regions, and the different Pomc constructs used (complete promoter, with RARE site or with 
BMPRE site only, and mutated BMPRE site or RARE site). (B and C) AtT-20 cells were co-transfected with Pomc-LUC constructs (500 ng) and RSV-β-gal 
vector (200 ng), and treated with BMP-4, RA or their combination as indicated. After 24-h treatment, luciferase activity was measured and normalized. 
Values indicating the mean ± s.e.m. of luciferase-to-β-galactosidase ratio of one representative experiment of three with similar results are shown. n.s, not 
significant; *P < 0.05; **P < 0.01; ***P < 0.001; ANOVA with Bonferroni contrast. (D) EMSA of binding reactions using RARE sequence of the Pomc promoter 
as probe and AtT-20 cell nuclear extracts (NE) treated with BMP-4, RA or their combination as indicated. Binding complex is indicated by an arrow. 
Anti-SMAD4, anti-RARB and anti-RXRA antibodies (2 µg) were used to disrupt the binding complex; anti-actin antibody was used as control. Unlabeled 
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transducers of the BMP-4 pathway. BMP-4 reduces the 
transcriptional activity of Pomc, enhancing the inhibitory 
effect of RA. RA receptors and SMAD proteins associate by 
forming transcriptional complexes that bind to the RARE 
consensus sequence in the Pomc promoter. Negative 
regulators of RA and BMP-4 pathways, COUP-TFI and 
TOB1, disrupt the combined transcriptional complexes 
reversing the Pomc inhibition.
RA has an inhibitory effect on tumoral growth in AtT-
20 pituitary corticotroph cells (Paez-Pereda et  al. 2001). 
The blockade of BMP-4 pathway by hampering Smad4 
diminishes the inhibitory effect of RA on tumoral cell 
Figure 4
COUP-TFI hampers the formation of transcriptional complexes between elements of the BMP-4 signaling pathway and RA receptors. (A and B) AtT-20 
cells were transfected with COUP-TFI expression vector or empty vector and treated for 24 h with BMP-4, RA or their combination as indicated. Cell 
lysates were IP with anti-SMAD4 (1 µg) (A) or anti-SMAD1 (1 µg) (B) and analyzed by WB. One representative of three independent experiments with 
similar results is shown. V, vehicle; B, 100 ng/mL BMP-4; R, 100 nM RA; BR, 100 ng/mL BMP-4 + 100 nM RA; M, mock. (C, D, E and F) AtT-20 cells were 
co-transfected with POMC-LUC (C) or RARE-LUC (D) or Pomc promoter with BMPRE deletion (E) or Pomc promoter with BMPRE mutation (F) reporter 
vector (500 ng), RSV-β-gal construct (200 ng) and COUP-TFI expression vector (400 ng) or empty vector and treated with BMP-4, RA or their combination as 
indicated. After 24-h treatment, luciferase activity was measured and normalized. Values indicating the mean ± s.e.m. of luciferase-to-β-galactosidase ratio 
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proliferation and RA induces the expression of BMP-4 
(Giacomini et  al. 2006). It was also demonstrated that 
both RA and BMP-4 inhibit Pomc transcription and ACTH 
production (Paez-Pereda et al. 2001, Nudi et al. 2005). In 
this paper, we demonstrate for the first time the molecular 
mechanism involved in the interaction of both pathways 
in regulating Pomc expression in corticoptrophs.
The involvement of retinoic mediators in the BMP 
signaling has been also observed in mechanisms such 
as chondrogenesis. RA produced the inhibition of the 
phosphorylation of SMAD2 and SMAD3 and increased 
expression of SMAD7, explaining the RA-induced 
hypochondrogenesis of embryonic mesenchymal cells in 
vitro and showing a role of RA signaling in the mechanism 
of regulation of TGFB3/SMAD pathway (Yu & Xing 2006). 
RARγ may function as coactivator of SMAD3 and SMAD4 
for TGFB-transactivation pathways in a ligand-specific 
manner (Pendaries et  al. 2003). RA is a known potent 
inhibitor of adipogenesis. The involvement of SMAD3 in 
the RA inhibition of pre-adypocites has been described 
(Marchildon et al. 2010).
The BMP–Smad pathway interaction with steroid 
receptors seems to be an important mechanism for 
its action. In lactotrophs, BMP-4 signaling exerts a 
stimulatory and pro-proliferative signal, in contrast 
to what is observed in corticotrophs (Giacomini et  al. 
2009). In these cells BMP-4 interacts with estrogens both 
for its proliferative action as well as for the regulation 
of the prolactin promoter (Paez-Pereda et  al. 2003, 
Giacomini et  al. 2009). BMP-4 also decreased follicle-
stimulating hormone (FSH) release in the sheep pituitary 
and amplified the suppression of FSH release and FSHB 
mRNA levels induced by 17β-estradiol in vitro (Faure et al. 
2005). The crosstalk between SMADs and esteroids in cell 
proliferation in other systems has also been described 
(Matsuda et al. 2001, Kang et al. 2002). In corticotrophs 
the interaction seems to show no ligand dependency in 
so far as the complexes are formed in both cellular and 
Figure 5
TOB1 disrupts the formation of transcriptional complexes between RA receptors and elements of the BMP-4 signaling. (A and B) AtT-20 cells were 
transfected with TOB1 expression vector or empty vector and treated for 24 h with BMP-4, RA or their combination as indicated. Cell lysates were IP with 
anti-SMAD4 (1 µg) (A) or anti-SMAD1 (1 µg) (B) and analyzed by WB. One representative of two independent experiments with similar results is shown. V, 
vehicle; B, 100 ng/mL BMP-4; R, 100 nM RA; BR, 100 ng/ml BMP-4 + 100 nM RA; M, mock. (C and D) AtT-20 cells were co-transfected with Pomc-LUC (C) or 
RARE-LUC (D) reporter vector (500 ng), RSV-β-gal construct (200 ng) and TOB1 expression vector (300 ng) or empty vector, and treated with BMP-4, RA or 
their combination as indicated. After 24-h treatment, luciferase activity was measured and normalized. Values indicating the mean ± s.e.m. of luciferase-to-
β-galactosidase ratio of one representative experiment of three with similar results are shown. n.s, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; 
ANOVA with Bonferroni contrast.
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nuclear extracts (IP and gel shift experiments, respectively) 
under no stimulus. Many nuclear receptors can bind and, 
under certain conditions, activate transcription events on 
the basal level, even in the absence of ligands (Rosenfeld 
et  al. 2006). As indicated by the SMAD6/7, SMAD4-DN 
and TOB1 experiments, as well as the phosphorylation of 
SMAD1/5, Smad factors are necessary for the action of RA. 
Cofactors of the SMAD–RA receptor complexes, which do 
not appear in the EMSA and coIP experiments, very likely 
are regulated by RA and BMP-4 and contribute to their 
potentiated action.
During embryogenic development, BMP proteins 
play a key role controlling several steps toward the 
constitution of a functional pituitary gland. BMP-2 and 
BMP-4 have been shown to participate in the initial 
steps of the development of the anterior pituitary 
(Scully & Rosenfeld 2002). BMP-4 is particularly critical 
during the developmental patterning of the pituitary, 
from the induction of Rathke’s pouch to cell specificity 
commitment in anterior lobe. The regulation in the 
expression and range of action of the factors present in 
this network governing the process is complex and the 
proper balance in the activity of BMP signaling is crucial 
in pituitary organogenesis (Davis & Camper 2007). Both 
BMP-4 and RA participate in multiple steps during pituitary 
development, controlling the circuitry of several signals 
Figure 6
RA and BMP-4 signaling pathways interaction in pituitary corticotroph cells. (A) Schematic representation of mouse Crh-r1 promoter (GenBank: 12921). In 
silico analysis displays one consensus sequence for RA (RARE site, white box) and four for BMP (BMPRE site, gray boxes). (B) AtT-20 cells or AtT-20 
SMAD4-DN stable clones were co-transfected with Crh-r1-LUC reporter vector (500 ng) and RSV-β-gal construct (200 ng) and treated with BMP-4, RA or 
their combination as indicated. After 24-h treatment, luciferase activity was measured and normalized. Values indicating the mean ± s.e.m. of luciferase-to-
β-galactosidase ratio of one representative experiment of three with similar results are shown. *P < 0.05; **P < 0.01; ***P < 0.001; ANOVA with Bonferroni 
contrast. (C) The proposed model of interaction between both RA and BMP-4 signaling pathways, in which the presence of the transcriptional complex 
formed by RA receptors and signal transducers SMADs on the RARE site triggers the inhibition of the transcriptional activity, while the presence of 
transcriptional modulators of both pathways, COUP-TFI for RA signaling and Tob1 for BMP-4 signaling, act to regulate and ameliorate the inhibitory effect 
of the interaction, and thus allowing Pomc transcription. Without ligands, these complexes have a constitutive binding probably without the cofactors 
induced by BMP-4 and RA that contribute to their potentiated action.
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aiming to enhance the differentiation and maturation 
processes, mediated by the induction of expression of 
several key transcription factors (Cushman & Camper 
2001, Suh et  al. 2002). RA controls BMP-2 and BMP-4 
regulation in embryonal carcinoma cells (Glozak & Rogers 
1996), and their combination favors smooth muscle cell 
differentiation by inducing apoptosis in neurons and glial 
cells (Glozak & Rogers 1998, 2001). Intriguingly, as we 
show in this work, these pathways interact in the adult 
cell, in particular in the undifferentiated tumoral cells.
In order to verify if the RA–BMP-4 signaling complex 
is specific for the Pomc gene or could be acting on other 
target genes in the corticotroph, we investigated the Crh-r1 
gene. This gene promoter also presents RARE and BMPRE 
motifs and when evaluated under RA or BMP-4 treatment 
showed similar inhibitory effects as well as a potentiated 
inhibition under the co-treatment. The sensitivities of 
these systems are presumably to be different as the Crh-
r1 gene promoter showed a significantly lower inhibitory 
threshold of concentrations for both compounds to 
achieve a blockade in the transcriptional activation, in 
comparison to those required for Pomc inhibition. Other 
genes, under the control of RA and BMP-4 might be 
under the regulation of similar RA receptors/SMAD 
crosstalk mechanisms.
It has been observed that COUP-TFI expression in 
the normal pituitary is the reason why RA does not act 
on these cells (Paez-Pereda et al. 2001). In contrast, it has 
been shown that most of the human corticotrophinoma 
samples (29 out of 34) have negative expression for 
COUP-TFI (Bush et  al. 2010). Therefore the clinical 
relevance of COUP-TFI could be a point to consider 
during the evaluation of a therapeutical approach. TOB1, 
a factor involved in osteoblast proliferation and bone 
formation processes, is a known BMP pathway inhibitor 
(Yoshida et al. 2000), and might have a potential role in 
the pituitary serving as a molecular tool to regulate BMP-4 
action in corticotrophs. BMP-4 not only participates in 
the RA but also in the somatostatin analogs signaling on 
corticotrophinomas (Tsukamoto et  al. 2010). Given the 
blocking action of TOB1 in the RA/BMP-4 interaction 
on Pomc transcription, its expression in tumoral 
corticotrophs could eventually hamper the clinical 
outcome of RA or other therapeutical scheme, underlying 
the significance of a proper biochemical characterization 
of the corticotrophinoma cases to be treated.
In conclusion, our study reveals a molecular 
mechanism in which the presence of co-regulatory 
elements of RA and BMP-4 signaling pathways interact 
to regulate Pomc transcriptional activity (Fig. 6C). 
The expression of the molecules involved in these 
regulatory mechanisms will impact on the outcome of the 
response and may be relevant in order to define therapeutic 
targets for the treatment of corticotrophinomas.
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